Skip to main content

Table 3 Clinical and parasitological outcomes by site and treatment group

From: Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy

  

Mutengene

Yaounde

Garoua

Treatment

group

SPAQ

SP

AQ

SPAQ

SP

AQ

SPAQ

SP

AQ

ETF

 

4

14

3

0

8

1

3

10

10

LCF

 

2

7

4

2

12

4

2

5

1

LPF

 

6

11

6

10

12

8

6

7

8

ACPR, D14 (PCR corrected)

 

82.5%

75.3%

88.3%

82.3%

88.0%

86.3%

81.7%

71.0%

72.0%

ACPR, D28 (PCR corrected)

 

81.9%

62.5%

79.2%

76.2%

67.5%

80.3%

80.9%

70.1%

71.2%

Gametocyte

D3

1

10

3

9

7

4

0

1

1

Carriage(n)

D7

2

11

4

7

14

6

0

2

1

 

D14

0

6

0

3

16

0

0

1

0

 

D28

0

1

0

0

4

0

0

0

0

 

%

2.4%

13.9%

5.0%

8.9%

14.5%

7.1%

0.0%

2.9%

1.4%

  1. A, B, C, were groups to which independently at each site drugs were randomly assigned. SP- Sulphadoxine-pyrimethamine, AQ - Amodiaquine, SPAQ- combination of AQ and SP. ETF - Early Treatment Failure, LCF - Late Clinical Failure, LPF- Late Parastological Failure, ACPR - Adequate Clinical and Parasitological Response.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us